Tumor Board Tuesday 2024: Breast Cancers

PROVIDER STATEMENT

Provided by Integrity CE, LLC and Tumor Board Tuesday.

DISCLOSURE OF COMMMERCIAL SUPPORT

Supported by educational grants from Astellas Pharma Global, AstraZeneca, Janssen Scientific Affairs, LLC, Lilly, Novartis, Seagen and Taiho Oncology.

MODERATORS

Michael J. Pishvaian, MD, PhD
Associate Professor, Department of Oncology
Director of the Gastrointestinal, Development Therapeutics, and Clinical Research Programs at the NCR
Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia

Johnathan Ebben, MD, PhD
Oncology Fellow
Division of Hematology, Oncology, and Palliative Care
University of Wisconsin-Madison
Madison, Wisconsin

SCHEDULE

#TumorBoardTuesday takes place on Tuesdays at 8 PM Eastern Time.

 

DateTopicFacultyDisclosuresConversations
Tuesday, October 22, 2024Focus: HER2 Low/Ultra Low
AMA credit
Paolo Tarantino, MD
Research Fellow
Breast Oncology Center
Dana-Farber Cancer Institute

Stefania Morganti, MD
Research Fellow
Dana-Farber Cancer Institute
Harvard Medical School
Broad Institute of MIT and Harvard
Paolo Tarantino, MD
Consultant: AstraZeneca, Daiichi Sankyo, Gilead, Lilly

Stefania Morganti, MD has no real or apparent conflicts to disclose.
Tuesday, August 27, 2024AI-resistant HR+/HER2- Advanced Breast Cancer
AMA credit
Maryam Lustberg, MD, MPH
Associate Professor of Medicine
Chief of Breast Medical Oncology
Yale Cancer Center

Mridula George, MD
Assistant Professor of Medicine
Rutgers Robert Wood Johnson Medical School
Rutgers Cancer Institute
Maryam Lustberg, MD, MPH
Consultant: AstraZeneca, Gilead, Lilly, Novartis, Pfizer

Mridula George, MD has no real or apparent conflicts to disclose
Tuesday, July 23, 2024Sequencing Therapies in HER2+ Metastatic Breast Cancer
AMA credit
Laura Huppert, MD
Assistant Professor
University of California, San Francisco

Kelsey Natsuhara, MD
Hematology & Oncology Fellow
University of California, San Francisco
Laura Huppert, MD
Advisory Board: AstraZeneca, Pfizer

Kelsey Natsuhara, MD has no real or apparent conflicts to disclose.
Tuesday, June 25, 2024Tx Options for HR+/HER2- mBC
AMA credit
Yara Abdou, MD
Assistant Professor
Breast Medical Oncologist
University of North Carolina at Chapel Hill
Lineberger Comprehensive Cancer Center

Prarthna Bhardwaj, MD, FACP
Fellow
University of Massachusetts
Chan Medical School - Baystate
Springfield, MA
Yara Abdou, MD
Advisor: AstraZeneca
Consultation: Exact Sciences

Prarthna Bhardwaj, MD, FACP has no real or apparent conflicts to disclose.
Tuesday, May 14, 2024CDK 4/6i in Early High-Risk Breast Cancer
AMA credit
Arielle Medford, MD
Medical Oncologist
Massachusetts General Hospital
Harvard Medical School

Ashley Odai-Afotey, MD
Oncology Fellow
Dana Farber Cancer Institute
Massachusetts General Hospital
Arielle Medford, MD
Consultation: AstraZeneca, Natera, Guardant Health, Illumina, Myriad Genetics

Ashley Odai-Afotey, MD has no real or apparent conflicts to disclose.
Tuesday, April 16, 2024HER2 Low Metastatic Breast Cancer: Interpretation & Treatment
AMA credit
Margaret Gatti-Mays, MD, MPH
The Division of Medical Oncology
The Ohio State University
Comprehensive Cancer Center

Nerea Lopetegui-Lia, MD
Hematology/Medical Oncology Fellow
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH
Margaret Gatti-Mays, MD, MPH
Advisory: GE Health

Nerea Lopetegui-Lia, MD has no real or apparent conflicts to disclose.

Stay tuned for upcoming conversations!

PROGRAM OVERVIEW

Oncologists and other clinicians who treat patients with breast cancers have generally adopted molecular profiling technologies offering insight into the molecular underpinning of all types of breast cancers. Considering the challenges of managing these tumor types, understanding these molecular alterations is critical to incorporating newly approved and emerging targeted agents, including immunotherapies. Yet, translating these findings into clinical applications can be challenging. Determining which potential biomarkers and/or druggable mutations in breast cancers that benefit patients is instrumental in improving patient outcomes. Oncologists need greater understanding and insight into the foundational genomic discoveries that underly the use of targeted entities.

Tumor Board Tuesday is a regularly scheduled, Twitter-based case discussion forum led by expert faculty modeled on the traditional tumor board presentation. Cases are based on realistic scenarios and supporting data is including for optimal treatment selection and patient management.

TARGET AUDIENCE

This activity is designed to meet the needs of medical, surgical and radiation oncologists, physician assistants, nurse practitioners, nurses and other healthcare providers involved in treatment and management of patients with breast cancer.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the certification period, participants must:

If you wish to claim credit for your participation in TBT conversations from February 27, 2024 – March 19, 2025, you can do so here: www.integrityce.com/TBTeval24

MEDIA

Internet

ACCREDITATION STATEMENT

Physician Continuing Education

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 6.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Michael L. Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Educational (Unbranded) Program Speaker: Novartis, Pfizer
Steering Committee: Astellas, Pionyr, Trisalus
Funding to Institution: Amgen, Arcus Bio, Biomed Valley, Boerhinger Ingelheim, Ideaya, Seattle Genetics, Merck, Novartis, Pfizer, RenovoRx, Repare Tx, Tesaro, Tizonia
Stock Ownership: Perthera, Inc.

Johnathan Ebben, MD, PhD
Other (CEO): NanoRED

The Integrity CE, LLC planners and managers and Tumor Board Tuesday patient planner do not have any financial relationships or relationships to products or devices with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC  does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.